said Monday that it's in compliance with
qualifications and won't be subject to a delisting hearing.
Nasdaq told the Cranbury, N.J., drugmaker
in mid-August that it faced delisting because it had failed to promptly file a second-quarter financial report with the
Securities and Exchange Commission
Kos attributed the delay to its review of accounting for stock options. The company recently filed its second-quarter 10-Q with the SEC, as well as an amended 10-K form for the 2005 fiscal year and an amended 10-Q form for the first quarter of 2006 to reflect restatements based on its stock-option review.
Kos also has restated yearly earnings for 2001 through 2004 based on the review.